Feasibility test for evaluating TKI concentration by dried blood spot from patients with hematological malignancies.

Feasibility test for evaluating TKI concentration by dried blood spot from patients with hematological malignancies. - Feasibility test for evaluating TKI concentration by dried blood spot from patients with hematological malignancies.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045520

Enrollment

Registered

2021-10-01

Start date

2021-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myelogenous leukemia, chronic lymphocytic leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with CML or CLL, who are treated with one of the designated TKIs (imatinib, dasatinib, nilotinib, bosutinib, ponatinib, ibrutinib). 2) 15 years old or older. 3) Agree with ICF.

Exclusion criteria

Exclusion criteria: 1) Disagree with ICF. 2) Patients who lack medical adherence. 3) Patients who are otherwise considered ineligible for the study by the investigator.

Design outcomes

Primary

Measure	Time frame
Possibility to measure TKI concentration by finger-prick DBS (dried blood sample)	—

Secondary

Measure	Time frame
Possibility to measure bcr-abl mRNA expression by finger-prick DBS (dried blood sample)	—

Countries

Japan

Contacts

Public ContactTakeshi Kondo

Aiiku Hospital Blood Disorders Center

kondo@aiiku-hp.or.jp+81-11-563-2211

Outcome results